Up to $818 million deal between J&J and Locus Biosciences points to a new path for CRISPR therapies

The agreement announced yesterday between Locus Biosciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) heralds a new path for CRISPR gene modification technologies and (potentially) the entire field of targeted microbiome therapies. Locus, headquartered in Research Triangle Park, North Carolina, commercializes research originally developed by North Carolina State University scientists, focused on Cas3 proteins, which devour Pac-Man-style DNA rather than to modify it, like the CRISPR, more known, based on Cas9 technologies used by companies such as Caribou Biosciences, Editas Medicine, Synthego, Intellia Therapeutics, CRISPR Therapeutics and Beam Therapeutics. While Cas9 CRISPR technologies can alter the targeted DNA

The post Up to $818 million deal between J&J and Locus Biosciences points to a new path for CRISPR therapies appeared first on viralamo.

http://bit.ly/2SCY7cH